Stock Analiz

China SXT Pharmaceuticals, Inc. SXTC

· IPO 2019 · data as of November 13, 2026

$3.00Market cap $310725
Open the interactive analysis →

China SXT Pharmaceuticals, Inc. (SXTC) is a company listed in the US with a market value of about $310725. In fiscal year 2026 it had revenue of $1M and net income of -$6M, a net margin of -545.2%.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -25% a year, a 5-year average ROIC of -20%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 60% below the current price.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals is listed in the US, IPO year 2019. Revenue went from $5M in 2017 to $1M in 2026, a decline of about 14.9% a year. It was profitable in 3 of the last 10 years in our data.

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.3
P/B0.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−60%

Growth and quality

Revenue growth (1 yr)-34.6%
Revenue growth (5 yrs, per year)-24.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-283.4%
ROIC (5-yr avg.)-19.7%
Profitable years (of last 10)3
Years paying a dividend—

Financials, last 10 years

Fiscal year2026202520242023202220212020201920182017
Revenue$1M$2M$2M$2M$3M$5M$5M$7M$7M$5M
Net income-$6M-$3M-$3M-$6M-$6M-$3M-$10M$2M$1M$1M
Free cash flow—-$2M-$2M—$207361-$1M$803408-$296633$1M$113866
EPS (diluted)$-59.91$-31.90$-29.92$-57.30$-55.38$-26.53$-99.33$14.86$11.47$11.44
Net margin-545.2%-189.8%-160.7%-301.0%-220.4%-57.5%-199.3%21.9%16.9%24.3%
ROIC-18.2%-12.9%-13.4%-28.6%-25.5%-12.8%-14.1%13.6%32.4%64.9%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is China SXT Pharmaceuticals stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 60% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does China SXT Pharmaceuticals pay a dividend?

Not currently.

Is China SXT Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. China SXT Pharmaceuticals scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.